Clinical Trial

DOUBLE BLIND TRIAL OF DEXTROMORAMIDE, METHADONE AND PETHIDINE IN THE TREATMENT OF SEVERE PAIN

*S. G. FLAVELL MATTS, M.B., Ch.B., M.R.C.P.(Ed.)

C. H. J. SWAN, M.B., Ch.B.

The Royal Hospital, Wolverhampton

B. A. WHARTON, M.B., Ch.B., D.C.H., The Middlesex Hospital, London, W.1

Severe pain is a recurrent problem in the treatment of many diseases, and its relief is an important part of the management of the illness. Many analgesics are in existence but few are really effective in therapy. Most people are still agreed that the drugs of the opiate group are probably the most effective for pain relief. Unfortunately, the use of these drugs is marred by the occurrence of unpleasant and sometimes dangerous side-effects, particularly respiratory depression, nausea, vomiting and addiction. It is extremely difficult to design a good clinical trial to discriminate between drugs used in the relief of pain. Uncontrolled trials are of no value because they depend too much on the subjective impressions of the patient and observers. Controlled trials are difficult to organise because of their time-consuming nature, difficulties with the D.D.A. regulations and the problems of assessing degrees and duration of pain relief. Many of these difficulties have been stressed in excellent reviews of the subject by Swerdlow and Murray (1962), and Swerdlow, Murray and Daw (1963). In view of the importance of obtaining accurate information on this subject, we felt that an investigation employing a double blind technique would be the best method of avoiding false clinical bias and erroneous impres-It was felt that a comparison of three commonly used oral analgesics would determine, by this method, any difference between them. Pethidine is very widely used and was therefore one of the drugs chosen. Methadone, which is another well-established and widely-used analgesic, was the second drug included in the trial. For the third drug we chose the relatively new analgesic dextromoramide (Palfium), which originated in Belgium and had been described by Janssen and Jageneau (1957, 1958). The use of dextromoramide has been described in this country by Cope and Jones (1959), Gavin (1960), Kagan (1961) and Matts (1962); and it has been found to be an effective and safe analgesic in clinical practice.

TABLE 1—Dextromoramide 10 mg.

TABLE I Dextromorating To mg.				
Diagnosis	Length of effects (hours)	Side-effects		
D		2771		
Raynaud's disease	3	Nil		
Diabetic gangrene	3	Nil		
Pleurisy	4 3	Nil		
Carcinomatosis	3	Nil		
Subarachnoid hæmorrhage	4 6	Nil		
Pleurisy		Dizziness		
Coronary thrombosis	6	Nausea		
Scleroderma	5	Nil		
Subarachnoid hæmorrhage	12	Nil		
Carcinomatosis	No	Nausea		
	effects			
Severe rheumatoid arthritis	5	Nil		
Diabetic gangrene	4	Nil		
Angina	4 6	Nil		
Cervical spondylosis	6	Nil		
Coronary thrombosis	6	Nil		
Pleurisy	4	Nil		
Subarachnoid hæmorrhage	3	Nil		
Cerebral tumour	3 3	Dizziness		
Severe migraine	4	Nil		
Cerebral hæmorrhage	4 6	Nil		
Subarachnoid hæmorrhage	12	Nil		
Gangrene	4	Nil		
Carcinomatosis	i	Nil		
Coronary thrombosis	2	Faintness and		
•		dizziness		
Pleurisy	4	Nil		
Lumbar spondylosis	.4	Nil		
Carcinomatosis		Nil		
Gangrene	3 2	Nil		
Pleurisy	I	Nil		
Subarachnoid hæmorrhage	8	Nil		

Summary

30 patients; 29 obtained relief of from 1 to 12 hours, 5 patients developed side-effects—no respiratory depression.

Method

Three lots of tablets were prepared externally completely identical. Each tablet contained either 5 mg. of

^{*}In receipt of a Research Grant from the Birmingham Regional Hospital Board.

TABLE 2-Methadone 10 mg.

TABLE 2—WIEU	TABLE 2—Internatione to mg.		
Diamosis	Length of effects	Side-effects	
Diagnosis	(hours)	Side-enects	
Pleurisy	I	Nil	
Severe angina	3	Nil	
Cerebral tumour	4	Sweating and	
		drop in B.P.	
Diabetic gangrene	I	Vomiting	
Severe rheumatoid arthritis	8	Nil	
Subarachnoid hæmorrhage	4	Nil	
Coronary thrombosis	3	Dizziness	
Pleurisy	3 6	Dizziness	
Carcinomatosis	8	Respiratory	
		depression	
Diabetic gangrene	12	Nil	
Carcinomatosis	3	Respiratory	
	"	depression	
Subarachnoid hæmorrhage	3	Nil	
Acute peptic ulcer	4	Nil	
Arteriosclerotic gangrene	No	Nil	
8 8	effects		
Severe Raynaud's			
phenomena	2	Sweating	
Severe migraine	3	Nil	
Pleurisy	4	Nil	
Coronary thrombosis	;	Vomiting	
Cerebral tumour	3	Nil	
Coronary thrombosis	4	Dizziness	
Severe rheumatoid arthritis	3	Nil	
Pleurisy	4	Nil	
Carcinoma of thyroid	5	Nil	
Subarachnoid hæmorrhage	5 3 4 3 4 5 4 3	Nil	
Severe angina	3	Nil	
Diabetic gangrene	4	Nil	
Sciatica	3	Nil	
Osteoporotic vertebral	3		
collapse	3	Nil	
Angina	1 1	Nil	
Carcinomatosis	4	Nil	
	<u>'</u> T		

Summary

30 patients; 29 obtained relief of pain from 1 to 12 hours, 9 experienced side-effects, two of which were respiratory depression.

dextromoramide, 5 mg. of methadone or 50 mg. of pethidine. The dosage range of dextromoramide is from 5 to 10 mg., of methadone 5 to 10 mg., and of pethidine 50 to 100 mg. In order to obtain a standard effect it was decided to give the upper range of dosage and therefore all patients would be treated with either 10 mg. of dextromoramide, 10 mg. of methadone or 100 mg. of pethidine, this dose being contained in two Thus all the patients were prescribed two tablets. tablets of one of these analgesics, which were identified by letters A, B or C. Only the pharmacist knew which was which of these and this knowledge was not revealed until after the entire trial was completed. Thus neither doctors, nurses nor patients were aware of the contents of the tablets at the time of the trial and The patients were those admitted to a assessment. general medical ward and were suffering with a variety of conditions which had produced severe pain. They were assessed by the authors and were adjudged as being in need of a powerful analgesic because of this severe pain. Having thus been included in the trial they were prescribed, by a method of random selection,

TABLE 3—Pethidine 100 mg.

D.	Length of effects	
Diagnosis	(hours)	Side-effects
Coronary thrombosis .	. 3	Nil
Pleurisy	. I	Dizziness
Angina	. 4	Dizziness
Diabetic gangrene .	. 4	Sweating
Pleurisy	. 3	Respiratory depression
Sciatica	. No	Nil
	effects	
Carcinomatosis	. 2	Nil
Paget's disease	. 8	Nil
Angina	. 3	Vomiting
Coronary thrombosis .	. 5	Nil
Arteriosclerotic gangrene.	. 4	Nil
Subarachnoid hæmorrhage		Nil
Severe migraine	. No	Nil
	effects	1 111
Severe migraine		Nil
Osteo-arthritis	3 6	Respiratory
	.	depression
Pleurisy	. 7	Nil
Diabetic gangrene .	. 3	Nil
Severe rheumatoid arthrit	is 4	Nil
Acute peptic ulcer .	. 5	Sweating
Coronary thrombosis .	. 9	Nil
Angina	. No	Nil
g	effects	1111
Subarachnoid hæmorrhage		Nil
a manufacture inclination of the	effects	1111
Carcinomatosis	. 8	Collapse with
	.	sweating
Pleurisy		Nil
Cervical spondylosis .	. 4	Nil
Coronary thrombosis	. 3	Nil
Cerebral tumour	. 3	Nil
Sciatica	. 4	Nil
Carcinomatosis	No No	Nil
	effects	1411
Axillary abscess	· 3	Nil

Summary

30 patients; 25 obtained relief of pain from 1 to 9 hours, 8 developed side-effects, 2 of which were respiratory depression.

either analgesic A, B or C. The results of therapy were recorded from the observations of the medical staff, nursing staff and the statements of the patients themselves as regards their feeling of relief from pain, the duration of this relief and the occurrence of any side-effects. An analysis of the results can be seen in Tables 1, 2, 3 and 4.

Results

As can be seen from the tables, differences between the three groups were not great. A total of 90 patients in all were included in the trial. In the dextromoramide group (30 patients) 29 patients obtained relief from pain and five patients developed side-effects, none of these being respiratory depression. In the methadone group (30 patients) 29 patients obtained relief of pain, 9 patients experienced side-effects, two of these being respiratory depression. In the pethidine group (30 patients) 25 patients obtained relief of pain and eight patients developed side-effects, two of which were

TABLE 4

Drug		Average duration of pain relief (hours)	
Dextromoramide 10 mg.		4.4	
Methadone 10 mg	• •	3.8	
Rethidine 100 mg	• •	3.6	

respiratory depression. The best average duration of relief of pain was dextromoramide with 4.4 hours, methadone came second with 3.8 hours and pethidine last with 3.6 hours.

Discussion

The use of oral analgesics is considerably larger than those given by injection because of their ease of administration. It is therefore important to know the relative efficacy and dangers of analgesics in common use. The trial results appear to confirm the clinical impression held by many people that there is little difference between the more powerful oral analgesics. However, dextromoramide does show marginal advantages over the other two agents. The average duration of pain relief was slightly higher, the incidence of side-effects lower and there were no cases in which respiratory depression was a feature. These findings may be of particular value outside hospital practice where patients will take analgesics as and when necessary for their pain in their own homes. In these circumstances the increased duration of pain relief with dextromoramide is particularly valuable and the reduction in the number of dangerous side-effects a feature which adds greatly to the safety, because the patients will not normally be under continuous surveillance, as they would be from the nursing staff in a hospital. The fact that there are so many oral analgesics makes it even more important that one should choose the best available drug for the type of pain experienced by the patient, taking into account the presence of various disease entities which may make other analgesics undesirable for various reasons (i.e. respiratory depression undesirable in pneumonia or pleurisy etc.).

Although it is said that 'man made aspirin, morphine came from heaven', a patient suffering severe side-effects from morphine may well feel that the direction of origin of morphine may have been reversed! For this reason alternatives to morphine should always be considered, and of these the three employed in this trial are acceptable, with the evidence pointing to a marginal advantage to dextromoramide, particularly in cardiorespiratory or cerebral conditions.

Summary

A double-blind trial of dextromoramide, pethidine and methadone in severe pain was carried out. The results are not strikingly different, but marginal advantages in favour of dextromoramide do emerge, particularly for home use or in cardiorespiratory or cerebral cases.

REFERENCES

COPE, E., and JONES, P. O. (1959): Relief of Post-operative Pain, Brit. med. J., i, 211.

GAVIN, R. (1960): The Alleviation of Intractable Pain, Ibid., ii, 1917.

JANSSEN, P. A. J., and JAGENEAU, A. H. (1957): A New Series of Potent Analgesics, J. Pharm. Pharmacol., 9, 381. —— (1958): A New Series of Potent Analgesics, Ibid, 10, 14.

KAGAN, G. (1961): Dextromoramide: a New Analgesic, Med. Press, 245, 154.

MATTS, S. G. F. (1962): Dextromoramide Analgesia in the Acute General Medical Patient, Practitioner, 188, 524. SWERDLOW, M., and MURRAY, A. (1962): 'Some Difficulties in the Assessment of Post-operative Pain', European Congress of Anæsthiology (Vienna), 1962.

-, ---, and Daw, R. H. (1963): A Study of Post-operative Pain, Acta anæsth. scand., 7, 1.